Victoria Sinibaldi

Research Associate

1987 …2018
If you made any changes in Pure, your changes will be visible here soon.

Research Output 1987 2018

Filter
Article
2017

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: An open-label, phase 2, multicohort study

Teply, B. A., Wang, H., Luber, B., Sullivan, R., Rifkind, I., Bruns, A., Spitz, A., DeCarli, M., Sinibaldi, V., Pratz, C. F., Lu, C., Silberstein, J. L., Luo, J., Schweizer, M. T., Drake, C. G., Carducci, M. A., Paller, C., Antonarakis, E., Eisenberger, M. & Denmeade, S. R., Jan 1 2017, (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journalArticle

Castration
Androgens
Prostatic Neoplasms
Therapeutics
MDV 3100
2016

Is there a "trial effect" on outcome of patients with metastatic renal cell carcinoma treated with sunitinib?

Keizman, D., Rouvinov, K., Sella, A., Gottfried, M., Maimon, N., Kim, J. J., Eisenberger, M., Sinibaldi, V., Peer, A., Carducci, M. A., Mermershtain, W., Leibowitz-amit, R., Weitzen, R. & Berger, R., 2016, In : Cancer Research and Treatment. 48, 1, p. 281-287 7 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Clinical Trials
Disease-Free Survival
Survival
Therapeutics

Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib

Keizman, D., Sarid, D., Lee, J. L., Sella, A., Gottfried, M., Hammers, H., Eisenberger, M., Carducci, M. A., Sinibaldi, V., Neiman, V., Rosenbaum, E., Peer, A., Neumann, A., Mermershtain, W., Rouvinov, K., Berger, R. & Yildiz, I., Oct 1 2016, In : Oncologist. 21, 10, p. 1212-1217 6 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Disease-Free Survival
Survival
Neutrophils
Lymphocytes
Castration
Androgen Receptors
Prostatic Neoplasms
Disease-Free Survival
Antigens
2015

Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma

Keizman, D., Ish-Shalom, M., Sella, A., Gottfried, M., Maimon, N., Peer, A., Hammers, H., Eisenberger, M., Sinibaldi, V., Neiman, V., Rosenbaum, E., Sarid, D., Mermershtain, W., Rouvinov, K., Berger, R. & Carducci, M. A., Nov 12 2015, (Accepted/In press) In : Clinical Genitourinary Cancer.

Research output: Contribution to journalArticle

Metformin
Renal Cell Carcinoma
Disease-Free Survival
Survival
Multivariate Analysis
2014

Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Hammers, H., Eisenberger, M., Sinibaldi, V., Pili, R., Hayat, H., Kovel, S., Sella, A., Boursi, B., Weitzen, R., Mermershtain, W., Rouvinov, K., Berger, R. & Carducci, M. A., 2014, In : Oncologist. 19, 1, p. 51-60 10 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Disease-Free Survival
Smoking
Hypertension
Survival

American Cancer Society prostate cancer survivorship care guidelines

Skolarus, T. A., Wolf, A. M. D., Erb, N. L., Brooks, D. D., Rivers, B. M., Underwood, W., Salner, A. L., Zelefsky, M. J., Aragon-Ching, J. B., Slovin, S. F., Wittmann, D. A., Hoyt, M. A., Sinibaldi, V., Chodak, G., Pratt-Chapman, M. L. & Cowens-Alvarado, R. L., 2014, In : Ca-A Cancer Journal for Clinicians. 64, 4, p. 225-249 25 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Survival Rate
Guidelines
Survivors
Aftercare

Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel

Peer, A., Gottfried, M., Sinibaldi, V., Carducci, M. A., Eisenberger, M., Sella, A., Leibowitz-Amit, R., Berger, R. & Keizman, D., 2014, In : Prostate. 74, 4, p. 433-440 8 p.

Research output: Contribution to journalArticle

docetaxel
Ketoconazole
Castration
Prostatic Neoplasms
Disease-Free Survival
2012

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma

Keizman, D., Ish-Shalom, M., Pili, R., Hammers, H., Eisenberger, M., Sinibaldi, V., Boursi, B., Maimon, N., Gottfried, M., Hayat, H., Peer, A., Kovel, S., Sella, A., Berger, R. & Carducci, M. A., May 2012, In : European Journal of Cancer. 48, 7, p. 1031-1037 7 p.

Research output: Contribution to journalArticle

Diphosphonates
Renal Cell Carcinoma
Disease-Free Survival
Neoplasm Metastasis
Bone and Bones

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: Association with outcome and predictive nomogram

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Rosenbaum, E., Kovel, S., Pili, R., Sinibaldi, V., Carducci, M. A., Hammers, H., Eisenberger, M. & Sella, A., 2012, In : Oncologist. 17, 12, p. 1508-1514 7 p.

Research output: Contribution to journalArticle

Nomograms
Ketoconazole
Castration
Prostatic Neoplasms
Neutrophils
2011
docetaxel
Castration
Prostatic Neoplasms
Appointments and Schedules
Bone and Bones
Androgens
Disease Progression
Prostatic Neoplasms
Therapeutics
Androgen Antagonists

TNF-blockade in patients with advanced hormone refractory prostate cancer

Diaz, L. A., Messersmith, W., Sokoll, L. J., Sinibaldi, V., Moore, S., Carducci, M. A. & Eisenberger, M., Feb 2011, In : Investigational New Drugs. 29, 1, p. 192-194 3 p.

Research output: Contribution to journalArticle

Neoplasm Drug Resistance
Neoplasm Staging
Interleukin-6
Prostatic Neoplasms
Tumor Necrosis Factor-alpha
2010

Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: Results of a phase I/II double-blinded, randomized study

Keizman, D., Zahurak, M., Sinibaldi, V., Carducci, M. A., Denmeade, S. R., Drake, C., Pili, R., Antonarakis, E., Hudock, S. & Eisenberger, M., Nov 1 2010, In : Clinical Cancer Research. 16, 21, p. 5269-5276 8 p.

Research output: Contribution to journalArticle

Prostate-Specific Antigen
Prostatic Neoplasms
Neutropenia
Population
Androgens
2008
Renal Cell Carcinoma
Therapeutics
2007

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer.

Sinibaldi, V., 2007, In : Clinical Interventions in Aging. 2, 4, p. 555-560 6 p.

Research output: Contribution to journalArticle

docetaxel
Prostatic Neoplasms
Hormones
SEER Program
Therapeutics
Prostatectomy
Prostatic Neoplasms
Radiotherapy
Recurrence
Prostate-Specific Antigen
Prostatic Neoplasms
Phosphotransferases
Therapeutics
Prostate
Prostatectomy
2006

Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma

Sinibaldi, V., Elza-Brown, K., Schmidt, J., Eisenberger, M., Rosenbaum, E., Denmeade, S. R., Pili, R., Walczak, J., Baker, S. D., Zahurak, M. & Carducci, M. A., Aug 2006, In : American Journal of Clinical Oncology: Cancer Clinical Trials. 29, 4, p. 395-398 4 p.

Research output: Contribution to journalArticle

docetaxel
Androgens
Prostate
Carcinoma
Prostatic Neoplasms

The role of cytotoxic chemotherapy in prostate cancer: A critical reevaluation 20 years later

Eisenberger, M. & Sinibaldi, V., 2006, In : Oncology. 20, 8, p. 853-862 10 p.

Research output: Contribution to journalArticle

Molecular Targeted Therapy
Prostate-Specific Antigen
Prostatic Neoplasms
Research Personnel
Hormones
2005

Marimastat in the treatment of patients with biochemically relapsed prostate cancer: A prospective randomized, double-blind, phase I/II trial

Rosenbaum, E., Zahurak, M., Sinibaldi, V., Carducci, M. A., Pili, R., Laufer, M., DeWeese, T. & Eisenberger, M., Jun 15 2005, In : Clinical Cancer Research. 11, 12, p. 4437-4443 7 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Prostate-Specific Antigen
Therapeutics
Matrix Metalloproteinase Inhibitors
Poisons
2004

A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma

Sunkara, U., Walczak, J. R., Summerson, L., Rogers, T., Eisenberger, M., Denmeade, S. R., Pili, R., Huff, C. A., Sinibaldi, V. & Carducci, M. A., Jan 2004, In : Journal of Interferon and Cytokine Research. 24, 1, p. 37-41 5 p.

Research output: Contribution to journalArticle

temozolomide
Renal Cell Carcinoma
Interferons
Chills
Melanoma

Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: Elevation of estradiol as possible mechanism of action

Eisenberger, M. A., Laufer, M., Vogelzang, N. J., Sartor, O., Thornton, D., Neubauer, B. L., Sinibaldi, V., Lieskovsky, G., Carducci, M. A., Zahurak, M. & Raghavan, D., Jan 2004, In : Urology. 63, 1, p. 114-119 6 p.

Research output: Contribution to journalArticle

Izonsteride
5-alpha Reductase Inhibitors
Clinical Pharmacology
Castration
Prostate-Specific Antigen
2002

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics

Carducci, M. A., Nelson, J. B., Bowling, M. K., Rogers, T., Eisenberger, M., Sinibaldi, V., Donehower, R. C., Leahy, T. L., Carr, R. A., Isaacson, J. D., Janus, T. J., Andre, A., Hosmane, B. S. & Padley, R. J., Apr 15 2002, In : Journal of Clinical Oncology. 20, 8, p. 2171-2180 10 p.

Research output: Contribution to journalArticle

Adenocarcinoma
Pharmacokinetics
Safety
Maximum Tolerated Dose
Headache

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

Sinibaldi, V., Carducci, M. A., Moore-Cooper, S., Laufer, M., Zahurak, M. & Eisenberger, M., Mar 1 2002, In : Cancer. 94, 5, p. 1457-1465 9 p.

Research output: Contribution to journalArticle

docetaxel
Estramustine
Androgens
Prostate
Phosphates
2001

A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule

Carducci, M. A., Gilbert, J., Bowling, M. K., Eisenberger, M., Sinibaldi, V., Sinibaldi, V., Donehower, R. C., Chen, T. L., Grochow, L. B. & Donehower, R. C., 2001, In : Clinical Cancer Research. 7, 10, p. 3047-3055 9 p.

Research output: Contribution to journalArticle

Phenylbutyrates
Appointments and Schedules
Pharmacology
Pharmacokinetics
Maximum Tolerated Dose

Clinical conduct and nursing quality of life in prostate cancer

Sinibaldi, V. & Arzoomanian, R. Z., 2001, In : Hematology/Oncology Clinics of North America. 15, 3, p. 573-581 9 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Nursing
Quality of Life
Nurses
Clinical Trials
2000

Complete androgen blockade for prostate cancer: What went wrong?

Laufer, M., Denmeade, S. R., Sinibaldi, V., Carducci, M. A. & Eisenberger, M., Jul 2000, In : Journal of Urology. 164, 1, p. 3-9 7 p.

Research output: Contribution to journalArticle

Androgens
Prostatic Neoplasms
Castration
Androgen Antagonists
Quality of Life
1999

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate- specific antigen working group

Bubley, G. J., Carducci, M. A., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., Hussain, M., Kaplan, R., Myers, C., Oh, W., Petrylak, D. P., Reed, E., Roth, B., Sartor, O., Scher, H., Simons, J. & 6 others, Sinibaldi, V., Small, E. J., Smith, M. R., Trump, D. L., Vollmer, R. & Wilding, G., Nov 1999, In : Journal of Clinical Oncology. 17, 11, p. 3461-3467 7 p.

Research output: Contribution to journalArticle

Phase II Clinical Trials
Prostate-Specific Antigen
Androgens
Prostatic Neoplasms
Guidelines
docetaxel
Estramustine
Prostatic Neoplasms
Phosphates
Hormones
Prostate-Specific Antigen
Disease Progression
Prostatic Neoplasms
Pain
Androgen Antagonists
1998

Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin

Sridhara, R., Eisenberger, M., Sinibaldi, V., Reyno, L. M. & Egorin, M. J., Jul 1998, In : Cancer Epidemiology Biomarkers and Prevention. 7, 7, p. 631-634 4 p.

Research output: Contribution to journalArticle

Suramin
Prostate-Specific Antigen
Prostatic Neoplasms
Biomarkers
Hormones
1996

A prospective study of suramin-induced peripheral neuropathy

Chaudhry, V., Eisenberger, M., Sinibaldi, V., Sheikh, K., Griffin, J. W. & Cornblath, D., 1996, In : Brain. 119, 6, p. 2039-2052 14 p.

Research output: Contribution to journalArticle

Suramin
Peripheral Nervous System Diseases
Prospective Studies
Investigational Drugs
Sural Nerve
Suramin
Signs and Symptoms
Prostatic Neoplasms
Therapeutics
Refractive Errors
Prostatic Neoplasms
Neoplasms
Therapeutics
Neoplasm Metastasis
Morbidity
1995

Combined carboplatin plus bleomycin and conventional radiotherapy for advanced carcinomas of the head and neck

Espinoza-Jacobs, M. C., Suntharalingam, M., Eisenberger, M., Sinibaldi, V. & Salazar, O. M., 1995, In : American Journal of Clinical Oncology: Cancer Clinical Trials. 18, 1, p. 52-55 4 p.

Research output: Contribution to journalArticle

Carboplatin
Bleomycin
Neck
Radiotherapy
Head

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin

Reyno, L. M., Egorin, M. J., Eisenberger, M., Sinibaldi, V., Zuhowski, E. G. & Sridhara, R., 1995, In : Journal of Clinical Oncology. 13, 9, p. 2187-2195 9 p.

Research output: Contribution to journalArticle

Suramin
Appointments and Schedules
Prostatic Neoplasms
Hormones
Lethargy

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

Sridhara, R., Eisenberger, M., Sinibaldi, V., Reyno, L. M. & Egorin, M. J., 1995, In : Journal of Clinical Oncology. 13, 12, p. 2944-2953 10 p.

Research output: Contribution to journalArticle

Suramin
Prostate-Specific Antigen
Prostatic Neoplasms
Biomarkers
Hormones

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

Eisenberger, M., Sinibaldi, V., Reyno, L. M., Sridhara, R., Jodrell, D. I., Zuhowski, E. G., Tkaczuk, K. H., Lowitt, M. H., Hemady, R. K., Jacobs, S. C., VanEcho, D. & Egorin, M. J., 1995, In : Journal of Clinical Oncology. 13, 9, p. 2174-2186 13 p.

Research output: Contribution to journalArticle

Suramin
Prostatic Neoplasms
Hormones
Disease Progression
Pharmacokinetics

Suramin

Eisenberger, M., Sinibaldi, V. & Reyno, L., 1995, In : Cancer Practice. 3, 3, p. 187-189 3 p.

Research output: Contribution to journalArticle

Suramin
Prostatic Neoplasms
Clinical Trials

The experience with suramin in advanced prostate cancer

Eisenberger, M., Reyno, L., Sinibaldi, V., Sridhara, R., Carducci, M. A. & Egorin, M., 1995, In : Cancer. 75, 7 SUPPL., p. 1927-1934 8 p.

Research output: Contribution to journalArticle

Suramin
Prostatic Neoplasms
Outpatients
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
1994

Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer

Jodrell, D. I., Reyno, L. M., Sridhara, R., Eisenberger, M., Tkaczuk, K. H., Zuhowski, E. G., Sinibaldi, V., Novak, M. J. & Egorin, M. J., Jan 1994, In : Journal of Clinical Oncology. 12, 1, p. 166-175 10 p.

Research output: Contribution to journalArticle

Suramin
Drug and Narcotic Control
Prostatic Neoplasms
Pharmacokinetics
Population
1993

Suramin, an active drug for prostate cancer: Interim observations in a phase I trial

Eisenberger, M., Reyno, L. M., Jodrell, D. I., Sinibaldi, V., Tkaczuk, K. H., Sridhara, R., Zuhowski, E. G., Lowitt, M. H., Jacobs, S. C. & Egorin, M. J., Apr 21 1993, In : Journal of the National Cancer Institute. 85, 8, p. 611-621 11 p.

Research output: Contribution to journalArticle

Phase I Trial
Suramin
Prostate Cancer
Toxicity
Dose
1992

Approaches to optimal dosing of hexamethylene bisacetamide

Conley, B. A., Egorin, M. J., Sinibaldi, V., Sewack, G., Kloc, C., Roberts, L., Zuhowski, E. G., Forrest, A. & Van Echo, D. A., Jan 1992, In : Cancer Chemotherapy and Pharmacology. 31, 1, p. 37-45 9 p.

Research output: Contribution to journalArticle

hexamethylene bisacetamide
Toxicity
Plasmas
Acidosis
Area Under Curve

Carboplatin in the treatment of squamous cell head and neck cancers

Aisner, J., Sinibaldi, V. & Eisenberger, M., 1992, In : Seminars in Oncology. 19, 1 SUPPL. 2, p. 60-65 6 p.

Research output: Contribution to journalArticle

Squamous Cell Neoplasms
Carboplatin
Head and Neck Neoplasms
Fluorouracil
Cisplatin

Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck

Kruter, F., Eisenberger, M., Sinibaldi, V., Engstrom, C., Jacobs, M., Abrams, J., Belani, C., Gray, W. & Krasnow, S., Jun 1992, In : Investigational New Drugs. 10, 2, p. 89-91 3 p.

Research output: Contribution to journalArticle

Thioguanine
Intravenous Infusions
Antiemetics
Leukopenia
Thrombocytopenia
Autoanalysis
False Negative Reactions
Suramin
Enzyme activity
Amylases
1990

Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function

Conley, B. A., Egorin, M. J., Sinibaldi, V. & Van Echo, D. A., Nov 1990, In : Investigational New Drugs. 8, 4, p. 365-367 3 p.

Research output: Contribution to journalArticle

Menogaril
Nogalamycin
Drug Administration Schedule
Investigational Drugs
Kidney Diseases
1989

A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer

Eisenberger, M., Krasnow, S., Ellenberg, S., Silva, H., Abrams, J., Sinibaldi, V., Van Echo, D. & Aisner, J., 1989, In : Journal of Clinical Oncology. 7, 9, p. 1341-1345 5 p.

Research output: Contribution to journalArticle

Carboplatin
Head and Neck Neoplasms
Methotrexate
Therapeutics
Ethics

Carboplatin (CBDCA) and radiotherapy for stage IV carcinoma of the head and neck: A phase I-II study

Jacobs, M. C., Eisenberger, M., Min Chu Oh, C. O., Sinibaldi, V., Gray, W., Elias, G. & Salazar, O. M., 1989, In : International Journal of Radiation Oncology, Biology, Physics. 17, 2, p. 361-363 3 p.

Research output: Contribution to journalArticle

Carboplatin
radiation therapy
Neck
Radiotherapy
cancer